← All trials
NCT04315480
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 12, 2020
- Primary completion
- Apr 9, 2020
- Completion date
- May 31, 2020
- First posted
- Mar 19, 2020
- Last posted
- Apr 13, 2020
- Enrollment
- 38
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Marche Polytechnic UniversityLead sponsor
- Marche Polytechnic UniversityReponsible party - principal investigator
- Marche Polytechnic UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.